Education
About Us
Working with TipRanks
Follow Us
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
RESEARCH TOOLSreports
Total Valuation
Santhera Pharmaceuticals Holding has a market cap or net worth of $118.01M. The enterprise value is CHF127.16M.
Market Cap$118.01M
Enterprise ValueCHF127.16M
Share Statistics
Santhera Pharmaceuticals Holding has 13,524,123 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,524,123
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santhera Pharmaceuticals Holding’s return on equity (ROE) is -1.52 and return on invested capital (ROIC) is -29.69%.
Return on Equity (ROE)-1.52
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-29.69%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee501.50K
Profits Per Employee-538.13K
Employee Count78
Asset Turnover0.26
Inventory Turnover0.92
Valuation Ratios
The current PE Ratio of Santhera Pharmaceuticals Holding is -3.75. Santhera Pharmaceuticals Holding’s PEG ratio is 0.04.
PE Ratio-3.75
PS Ratio0.00
PB Ratio-1.92
Price to Fair Value5.68
Price to FCF-2.49
Price to Operating Cash Flow-2.82
PEG Ratio0.04
Income Statement
In the last 12 months, Santhera Pharmaceuticals Holding had revenue of 39.12M and earned -41.97M in profits. Earnings per share was -3.69.
Revenue39.12M
Gross Profit22.96M
Operating Income-33.38M
Pretax Income-41.66M
Net Income-41.97M
EBITDA-15.89M
Earnings Per Share (EPS)-3.69
Cash Flow
In the last 12 months, operating cash flow was -35.53M and capital expenditures -151.00K, giving a free cash flow of -35.68M billion.
Operating Cash Flow-35.53M
Free Cash Flow-35.68M
Free Cash Flow per Share-2.64
Dividends & Yields
Santhera Pharmaceuticals Holding pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.29
52-Week Price Change23.23%
50-Day Moving Average13.47
200-Day Moving Average12.18
Relative Strength Index (RSI)36.25
Average Volume (3m)27.44K
Important Dates
Santhera Pharmaceuticals Holding upcoming earnings date is Sep 10, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateSep 10, 2025
Ex-Dividend Date―
Financial Position
Santhera Pharmaceuticals Holding as a current ratio of 1.64, with Debt / Equity ratio of -101.72%
Current Ratio1.64
Quick Ratio1.26
Debt to Market Cap0.25
Net Debt to EBITDA0.02
Interest Coverage Ratio-1.66
Taxes
In the past 12 months, Santhera Pharmaceuticals Holding has paid 312.00K in taxes.
Income Tax312.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Santhera Pharmaceuticals Holding EV to EBITDA ratio is -9.88, with an EV/FCF ratio of -4.40.
EV to Sales4.01
EV to EBITDA-9.88
EV to Free Cash Flow-4.40
EV to Operating Cash Flow-4.42
Balance Sheet
Santhera Pharmaceuticals Holding has $40.92M in cash and marketable securities with CHF40.62M in debt, giving a net cash position of -$305.00K billion.
Cash & Marketable Securities$40.92M
Total DebtCHF40.62M
Net Cash-$305.00K
Net Cash Per Share-$0.02
Tangible Book Value Per Share$2.43
Margins
Gross margin is 51.93%, with operating margin of -85.34%, and net profit margin of -107.30%.
Gross Margin51.93%
Operating Margin-85.34%
Pretax Margin-106.51%
Net Profit Margin-107.30%
EBITDA Margin-40.62%
EBIT Margin-55.05%
Analyst Forecast
The average price target for Santhera Pharmaceuticals Holding is $30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.00
Price Target Upside149.18% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-62.17%
EPS Growth Forecast-166.33%